#USA #DJS Law Group #Eastchester #Savara Inc. #SVRA

Savara Inc. Faces Class Action Lawsuit

On October 13, 2025, it was announced that Savara Inc. is facing a class action lawsuit due to purported violations of federal securities laws. This legal action highlights significant claims that the company made misleading statements regarding its business practices, particularly concerning the submission of a Biologics License Application (BLA) to the FDA for its product MOLBREEVI.

Background on the Case

The lawsuit, initiated by the DJS Law Group, specifically alleges that Savara did not provide adequate information in its BLA. In particular, critical details regarding chemistry and manufacturing practices were not fully disclosed. This lack of transparency raised doubts about whether the FDA would approve the application, making the company's positive assertions to investors particularly deceptive. Investors who purchased stock in Savara during the designated class period of March 7, 2024, to May 23, 2025, may have been misled by these false statements and are encouraged to contact DJS Law Group to discuss potential recovery options.

Key Details

• - Class Period: March 7, 2024 - May 23, 2025
• - Deadline for Participation: November 10, 2025

Savara's shareholders are invited to join the class action in order to hold the company accountable for alleged losses incurred due to these reported misrepresentations. Interested parties will be enrolled in a portfolio monitoring service which keeps track of the legal proceedings and provides regular updates regarding the case's status. Participation does not carry any cost or obligation, making it accessible for affected investors.

Why Join the Class Action?

Joining a class action can be a strategic choice for those who might feel overwhelmed navigating individual lawsuits against larger corporations. The DJS Law Group specializes in securities class actions and corporate governance. Their experience ensures that the rights of shareholders will be effectively represented, maximizing the potential for compensation from any losses.

Despite uncertainties surrounding investment in biotech companies, Savara has attracted attention due to its focus on addressing unmet medical needs. However, the current legal challenges pose risks for existing and potential investors. DJS Law Group’s commitment to balanced counseling and aggressive advocacy looks to uphold investor interests during this turbulent time.

If you are a shareholder of Savara and have experienced a loss during the class period mentioned, now is the time to take action. Contact the DJS Law Group to discuss your rights and learn more about how to participate in this critical lawsuit.

For more details, reach out directly to the DJS Law Group at their Eastchester office:

• - Address: 274 White Plains Road, Suite 1, Eastchester, NY 10709
• - Phone: 914-206-9742
• - Email: [email protected]

Stay informed and protect your investments as this case unfolds. Together, investors can seek justice and recovery against any wrongdoing that may have impacted their financial well-being.